Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_assertion type Assertion NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_head.
- NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_assertion wasGeneratedBy ECO_0000203 NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_provenance.
- NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_assertion wasDerivedFrom befree-2016 NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_provenance.
- NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_assertion SIO_000772 17214581 NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_provenance.
- NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_assertion evidence source_evidence_literature NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_provenance.
- NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_assertion description "[Results from phase-II clinical trials with a BLyS antagonist in human SLE and RA have shown the antagonist to have biological and clinical activity along with a favorable safety profile.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP588110.RAUP3mAovUu1bZgNxhfYl8UbjyG9eCdB6oMlTNyjVg4A4130_provenance.